JAK1 and myelofibrosis: Ruxolitinib was the first JAK1/2 inhibitor that has been approved for the treatment of intermediate or high-risk myelofibrosis [17], including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis.